Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. - Wikidata - awgldk - TriplyDB

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

http://www.wikidata.org/entity/Q27851767

about

SYK is a critical regulator of FLT3 in acute myeloid leukemia Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer Acute Myeloid Leukemia: A Concise Review Next-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us?Pediatric AML: From Biology to Clinical Management Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy Targeted therapies in CLL: mechanisms of resistance and strategies for management Childhood acute myeloid leukaemia Progress in acute myeloid leukemia FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?CIViC database Dual kinase-bromodomain inhibitors for rationally designed polypharmacology Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.Novel therapeutic options in Acute Myeloid Leukemia Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia Targeting the TAM Receptors in Leukemia Secondary mutations as mediators of resistance to targeted therapy in leukemia FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations Targeting oncoprotein stability overcomes drug resistance caused by FLT3 kinase domain mutations Internal Tandem Duplication in FLT3 Attenuates Proliferation and Regulates Resistance to the FLT3 Inhibitor AC220 by Modulating p21Cdkn1a and Pbx1 in Hematopoietic Cells Limitations of the human reference genome for personalized genomics Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing.MICADo - Looking for Mutations in Targeted PacBio Cancer Data: An Alignment-Free Method Myeloid neoplasias: what molecular analyses are telling us Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.Functions of flt3 in zebrafish hematopoiesis and its relevance to human acute myeloid leukemia.Quality Control of the Traditional Patent Medicine Yimu Wan Based on SMRT Sequencing and DNA Barcoding Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.Niche-mediated depletion of the normal hematopoietic stem cell reservoir by Flt3-ITD-induced myeloproliferation.Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.Expanding the computational toolbox for mining cancer genomes.The Biology and Targeting of FLT3 in Pediatric Leukemia.BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells The Future of Targeting FLT3 Activation in AML.

P2860

d80b80b150ca12ecef04a7643e15429eed80491a

P248

Q24337247-BF8B447B-DB23-446D-8B5C-A57A89EC836C Q26746010-F113CA8C-D5E5-4085-BF52-640F1032D247 Q26766719-E40AC5B8-3199-4A26-880B-10C721B1D52B Q26781271-BFF8C738-6800-4D63-9FC9-6C22B26FB3AA Q26799773-5ED178B7-5859-4BF9-9FAF-5BD36B1CB2CC Q26991736-0754F76C-50A6-481A-8F6B-DE2BE7F4A64E Q27002528-98197CCD-6A7E-4EC3-A3E2-DBD7DCAA86BD Q27005960-1A02F011-00AE-4A9D-8B1A-F8CFEB8F7336 Q27024006-C6AAE589-9828-455A-AD8B-06B28F4AF886 Q27028163-1948504E-1B41-470C-8427-0D282C5E5C05 Q27612411-2168E795-E409-49EB-9C77-4A7E897CC59E Q27681935-720E6E29-9C6D-4F96-9D79-8F26F77307FF Q27852087-ED337E8D-C69E-4F09-B2B9-A2BD9F19796C Q27852520-725D0EC9-80D0-4E1F-A585-230EF697F1F3 Q27853011-F1A5785A-5378-476B-9B02-EC742BF41FEB Q27853214-DA92CF47-F025-46E9-995E-BC392B719704 Q28069889-733DC6E4-F6F2-4C0B-95BD-E7E73D4D9AA6 Q28075654-7D6C1574-DD8A-4637-BC3A-1BADBA2CFBE2 Q28078654-9DF66AF2-DD97-4FB5-B500-87229909BFA7 Q28087213-EBB8A636-4ECC-4DD6-9C60-57EFD43527D6 Q28289859-EA15ACF4-E76E-4F26-92D4-9741805D7CBD Q28539032-8A4DE9BC-A958-44B7-9730-77640EC63018 Q28552425-B1823AF6-DCF1-4B41-AF14-32705EDA737B Q28727242-EFA129A3-69AA-4EC2-8BA7-E6D6743E0E08 Q30843427-C413A81F-7B5B-4456-889E-B1105CFCCE4C Q31150879-73BAF4D9-8A72-436B-ADA5-1E870FE32D68 Q33354547-7E532A61-DD12-4CF6-8867-468BB6E31915 Q33442949-8936210C-F358-461C-8FD9-66B57B7CEF1D Q33595837-6B5E5111-B74D-4272-948F-649856EA289B Q33740701-AE16DBDA-68BD-48A6-9E33-A9B4D1A881A6 Q33767026-FE49EADA-CF27-43CB-B833-D2A90BDB54D3 Q33886530-476FA15F-DBC5-4EE2-BF8C-729B73A41FAF Q33903030-F45A8EF2-113D-4013-A00C-F73532AD711C Q33943277-96681EC5-7FA1-487F-875D-1BF2C90AACF5 Q34011740-D50CDB05-5BD8-4F07-964F-604E97D90C02 Q34207474-AF506D90-AA32-4C16-9D54-2A0486216716 Q34229555-4846BF5F-1078-4472-B96D-7494295C0838 Q34289202-7EF5345F-874B-4EF2-BB98-FBE04FC3AA23 Q34502608-3EA2289C-C5E5-4C1D-B9B2-7892F1CF84AF Q34555386-3F6D0259-4C0B-4A6B-A09E-7661F590ED28

P2860

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

http://www.wikidata.org/entity/Q27851767

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Validation of ITD mutations in ...... human acute myeloid leukaemia.

@ast

Validation of ITD mutations in ...... human acute myeloid leukaemia.

@en

Validation of ITD mutations in ...... human acute myeloid leukaemia.

@nl

type

label

Validation of ITD mutations in ...... human acute myeloid leukaemia.

@ast

Validation of ITD mutations in ...... human acute myeloid leukaemia.

@en

Validation of ITD mutations in ...... human acute myeloid leukaemia.

@nl

altLabel

Validation of ITD mutations in ...... human acute myeloid leukaemia

@en

prefLabel

Validation of ITD mutations in ...... human acute myeloid leukaemia.

@ast

Validation of ITD mutations in ...... human acute myeloid leukaemia.

@en

Validation of ITD mutations in ...... human acute myeloid leukaemia.

@nl

P1433

Q27851767-48D99B4E-F271-4B63-81A0-7EF37DF7F2A4

P1476

Q27851767-3C48BBBB-CDEB-41F0-81A5-42AE35992FEF

P2093

Q27851767-11C0A4C7-5FD5-4DA4-9B2E-B37288ADE10C

Q27851767-194A7632-8BD3-45CA-8F76-A1CEEF761425

Q27851767-1D616204-740D-447B-84EE-BBFF1845E2B0

Q27851767-22F65A92-EDD6-4F89-9231-6BAC78D38E1E

Q27851767-26D94A5E-FF7E-4E24-8C98-BE9294A0D6C2

Q27851767-45843087-E3B4-442F-90F6-E83EE19E787C

Q27851767-5DEF8618-B14D-4F5A-9032-5C484BFED162

Q27851767-604412FC-5501-40D4-97B3-F8F38F67AD63

Q27851767-7C70F154-D9D2-4409-A005-2DE406A7D141

Q27851767-8112FD5F-7945-4601-BAC6-2C65F20B1A2C

P2860

Q27851767-04223011-11AC-40CA-94F1-D24DC7CE87BD

Q27851767-11FA02AB-1107-4615-87FE-55D232CF7A25

Q27851767-18BF0916-53F1-4EC8-8DBA-31BC146BFCBE

Q27851767-22353883-DD69-4B06-A691-D5CD6D840737

Q27851767-2478F0C4-40FA-4356-9023-346395DCBA0F

Q27851767-30A3417B-7841-4D9F-BEFD-2F8A4A5A2DA9

Q27851767-31042E8E-E16B-4A65-8E4B-C3D36038E8F0

Q27851767-36D894CA-41D2-49F7-99F4-9E6C1F34BF20

Q27851767-3B95EEA2-FB50-4111-B669-3ADC521F9E50

Q27851767-4191631B-1507-46EB-B1C1-AB9D716FFFC7

P2888

Q27851767-BD41D673-8089-4825-86E4-E1D86774B056

P304

Q27851767-B6184F97-83C0-4938-A7E2-FA90E8519A0A

P31

Q27851767-AD8E928B-C2CB-4EBC-A2E1-59F9153B55C8

P3181

Q27851767-11115B82-74E6-4EA5-A6DE-8C013AB1609A

P356

Q27851767-C9A875BA-1E91-4F02-BDC6-5E96B3AF2A3F

P407

Q27851767-5083DDC8-A4A7-47C3-A182-1BDFC58D7B8B

P433

Q27851767-D364AA4B-F172-4851-9B2C-888B7DF92F9A

P478

Q27851767-AB49A540-18CB-4683-B4B5-6B5EB543C640

P50

Q27851767-29C1652B-5EE1-42F9-B6F4-7D097D669D1A

Q27851767-FA9E3DC2-5023-4607-B36B-5BD1B8FD116A

P577

Q27851767-169B6D92-4002-4C3D-B31B-E33AFAA99E80

P5875

Q27851767-09986B56-08A2-45F4-8599-C68C3FE0C863

P6179

Q27851767-8297DFAD-AA0B-493A-94DB-08FB616254AA

P698

Q27851767-EAFA00BC-5082-4728-BDD5-768A14CBD1C0

P921

Q27851767-D0A1F8FF-B5D7-48CB-B0A3-CBAAF15DBBD0

P932

Q27851767-C5C0A422-CFB9-4BA1-8D91-8F1825173367

P3181

P356

P1433

P1476

Validation of ITD mutations in ...... human acute myeloid leukaemia.

@en

P2093

Alexander E Perl

http://www.w3.org/2001/XMLSchema#string

Catherine C Smith

http://www.w3.org/2001/XMLSchema#string

Chen-Shan Chin

http://www.w3.org/2001/XMLSchema#string

Eric E Schadt

http://www.w3.org/2001/XMLSchema#string

Jeremy P Hunt

http://www.w3.org/2001/XMLSchema#string

Kevin J Travers

http://www.w3.org/2001/XMLSchema#string

Lauren E Damon

http://www.w3.org/2001/XMLSchema#string

Mark J Levis

http://www.w3.org/2001/XMLSchema#string

Neil P Shah

http://www.w3.org/2001/XMLSchema#string

Patrick P Zarrinkar

http://www.w3.org/2001/XMLSchema#string

P2860

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Structure of a c-kit product complex reveals the basis for kinase transactivation

The structural basis for autoinhibition of FLT3 by the juxtamembrane domain

Crystal structure of the tyrosine kinase domain of the human insulin receptor

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

PRODRG: a tool for high-throughput crystallography of protein-ligand complexes

Tandem repeats finder: a program to analyze DNA sequences

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

P2888

P304

260-3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

220370

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NATURE11016

http://www.w3.org/2001/XMLSchema#string

P407

P433

7397

http://www.w3.org/2001/XMLSchema#string

P478

485

http://www.w3.org/2001/XMLSchema#string

P50

Andrew Kasarskis

P577

2012-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224037978

http://www.w3.org/2001/XMLSchema#string

P6179

1041040113

http://www.w3.org/2001/XMLSchema#string

P698

22504184

http://www.w3.org/2001/XMLSchema#string

P921

P932

3390926

http://www.w3.org/2001/XMLSchema#string